Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박준범 | * |
dc.date.accessioned | 2023-01-06T16:30:07Z | - |
dc.date.available | 2023-01-06T16:30:07Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 0513-5796 | * |
dc.identifier.other | OAK-32805 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/263063 | - |
dc.description.abstract | Purpose: Advanced chronic kidney disease (CKD), including end-stage renal disease (ESRD) on dialysis, increases thromboem-bolic risk among patients with atrial fibrillation (AF). This study examined the comparative safety and efficacy of direct-acting oral anticoagulant (DOAC) compared to warfarin or no oral anticoagulant (OAC) in AF patients with advanced CKD or ESRD on dialysis. Materials and Methods: Using data from the COmparison study of Drugs for symptom control and complication prEvention of AF (CODE-AF) registry, 260 non-valvular AF patients with advanced CKD (defined as estimated glomerular filtration rate <30 mL/min per 1.73/m2) or ESRD on dialysis were enrolled from June 2016 to July 2020. The study population was categorized into DOAC, warfarin, and no OAC groups; and differences in major or clinically relevant non-major (CRNM) bleeding, stroke/systemic embolism (SE), myocardial infarction/critical limb ischemia (CLI), and death were assessed. Results: During a median 24 months of follow-up, major or CRNM bleeding risk was significantly reduced in the DOAC group compared to the warfarin group [hazard ratio (HR) 0.11, 95% confidence interval (CI) 0.01 to 0.93, p=0.043]. In addition, the risk of composite adverse clinical outcomes (major or CRNM bleeding, stroke/SE, myocardial infarction/CLI, and death) was significantly reduced in the DOAC group compared to the no OAC group (HR 0.16, 95% CI 0.03 to 0.91, p=0.039). Conclusion: Among AF patients with advanced CKD or ESRD on dialysis, DOAC was associated with a lower risk of major or CRNM bleeding compared to warfarin and a lower risk of composite adverse clinical outcomes compared to no OAC. ClinicalTrials.gov (NCT02786095). © Yonsei University College of Medicine 2023. | * |
dc.language | English | * |
dc.publisher | Yonsei University College of Medicine | * |
dc.subject | Anticoagulant | * |
dc.subject | atrial fibrillation | * |
dc.subject | bleeding | * |
dc.subject | dialysis | * |
dc.subject | stroke | * |
dc.title | Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease: CODE-AF Registry | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 64 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 18 | * |
dc.relation.lastpage | 24 | * |
dc.relation.journaltitle | Yonsei Medical Journal | * |
dc.identifier.doi | 10.3349/ymj.2022.0455 | * |
dc.identifier.scopusid | 2-s2.0-85144641346 | * |
dc.author.google | Park H. | * |
dc.author.google | Yu H.T. | * |
dc.author.google | Kim T.-H. | * |
dc.author.google | Park J. | * |
dc.author.google | Park J.-K. | * |
dc.author.google | Kang K.-W. | * |
dc.author.google | Shim J. | * |
dc.author.google | Kim J.-B. | * |
dc.author.google | Kim J. | * |
dc.author.google | Choi E.-K. | * |
dc.author.google | Park H.W. | * |
dc.author.google | Lee Y.S. | * |
dc.author.google | Joung B. | * |
dc.contributor.scopusid | 박준범(55131469900) | * |
dc.date.modifydate | 20240429132147 | * |